← Leaderboards
George A Burghen
University Of Tennessee Health Sci Ctr
$16,796
Attributed
$16,796
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$16,796 · 3
By mechanism
M01$16,796 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Abbas E. Kitabchi$15,006,255
- Karen C Johnson$29,379,620
- Linda K. Myers$3,788,393
- Robert W. W Williams$30,910,045
- Melissa S Faulkner$2,257,688
Others in their field
Top investigators on “Insulin Dependent Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$604,626,891
- John M Lachin · George Washington University$152,707,971
- David M Nathan · Massachusetts Institute Of Technology$142,449,293
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Marinella Temprosa · George Washington University$65,495,338
- Rose A Gubitosi-Klug · Case Western Reserve University$65,228,131
Research focus
Insulin Dependent Diabetes MellitusHuman Therapy EvaluationClinical ResearchHuman SubjectDiabetes Mellitus TherapyImmunotherapyChemopreventionDiabetes Mellitus GeneticsDisease /Disorder Prevention /ControlDrug Screening /EvaluationOutcomes ResearchPancreatic IsletsClinical TrialsOral AdministrationAutoimmunityInsulinPatient Oriented ResearchFamily GeneticsGenetic SusceptibilityAntigens
Grant awards (5)
Diabetes Prevention Trial - Type I Diabetes$454
M01 · FY2004 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$0
M01 · FY2001 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION$0
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES$16,342
M01 · FY2000 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION$0
M01 · FY2000 · RR